ישראל - עברית - Ministry of Health

perrigo israel agencies ltd - milnacipran hydrochloride - קפסולות - milnacipran hydrochloride 25 mg - milnacipran - milnacipran - treatment of major (i.e. all characteristics) depressive episodes in adults over 18 years old.

ישראל - עברית - Ministry of Health

perrigo israel agencies ltd - milnacipran hydrochloride - קפסולות - milnacipran hydrochloride 50.0 mg - milnacipran - milnacipran - treatment of major (i.e. all characteristics) depressive episodes in adults over 18 years old.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - bupropion hydrochloride - טבליה - bupropion hydrochloride 150 mg - bupropion - bupropion - wellbutrin xr is indicated for the treatment of major depresive episodes.following satisfactory response, continuation with wellbutrin xr therapy is effective in preventing relapse.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - bupropion hydrochloride - טבליה - bupropion hydrochloride 300 mg - bupropion - bupropion - wellbutrin xr is indicated for the treatment of major depresive episodes.following satisfactory response, continuation with wellbutrin xr therapy is effective in preventing relapse.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - ziprasidone as hydrochloride monohydrate - קפסולות - ziprasidone as hydrochloride monohydrate 40 mg - ziprasidone - ziprasidone - • schizophrenia. treatment of schizophrenia and for maintenance of clinical improvement during continuation therapy. • bipolar mania. ziprasidone is indicated as monotherapy in the treatment of manic or mixed episodes associated with bipolar disorder with or without psychotic features.• bipolar disorder. maintenance treatment of bipolar disorder, as an adjunct to lithium or valproate.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - ziprasidone as hydrochloride monohydrate - קפסולות - ziprasidone as hydrochloride monohydrate 60 mg - ziprasidone - ziprasidone - • schizophrenia. treatment of schizophrenia and for maintenance of clinical improvement during continuation therapy. • bipolar mania. ziprasidone is indicated as monotherapy in the treatment of manic or mixed episodes associated with bipolar disorder with or without psychotic features.• bipolar disorder. maintenance treatment of bipolar disorder, as an adjunct to lithium or valproate.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - ziprasidone as hydrochloride monohydrate - קפסולות - ziprasidone as hydrochloride monohydrate 80 mg - ziprasidone - ziprasidone - • schizophrenia. treatment of schizophrenia and for maintenance of clinical improvement during continuation therapy. • bipolar mania. ziprasidone is indicated as monotherapy in the treatment of manic or mixed episodes associated with bipolar disorder with or without psychotic features.• bipolar disorder. maintenance treatment of bipolar disorder, as an adjunct to lithium or valproate.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - ziprasidone as hydrochloride monohydrate - קפסולות - ziprasidone as hydrochloride monohydrate 20 mg - ziprasidone - ziprasidone - • schizophrenia. treatment of schizophrenia and for maintenance of clinical improvement during continuation therapy. • bipolar mania. ziprasidone is indicated as monotherapy in the treatment of manic or mixed episodes associated with bipolar disorder with or without psychotic features.• bipolar disorder. maintenance treatment of bipolar disorder, as an adjunct to lithium or valproate.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - eplerenone 25 mg - film coated tablets - eplerenone - inspra is indicated, in addition to standard therapy including beta-blockers, to reduce the risk of cardiovascular mortality and morbidity in stable patients with left ventricular dysfunction (lvef < 40 % ) and clinical evidence of heart failure after recent myocardial infarction.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - eplerenone 50 mg - film coated tablets - eplerenone - inspra is indicated, in addition to standard therapy including beta-blockers, to reduce the risk of cardiovascular mortality and morbidity in stable patients with left ventricular dysfunction (lvef < 40 % ) and clinical evidence of heart failure after recent myocardial infarction.